Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772304 · ClinicalTrials.gov registry record · Phase 4
Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
A Phase 4 study of Allergic Rhinitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT00772304: Completed Phase 4 study of Allergic Rhinitis, sponsored by Alcon Research.
NCT00772304 is a Phase 4 study of Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 102 participants, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00772304, a Phase 4 study of Allergic Rhinitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.
Primary Outcome
Using a set of coded responses, subjects evaluated product preference in regards to immediate taste
Conditions Studied
Interventions
- DRUG Olopatadine 0.6% / Azelastine 137 mcg
Study Locations (1)
Texas
- Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2008-10 |
| Phase | Phase 4 |
What the finished NCT00772304 record still lists
NCT00772304 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which Olopatadine 0.6% / Azelastine 137 mcg is the first listed.
NCT00772304 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00772304 about?
NCT00772304 is a clinical study titled "Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis". To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.
What is the current status of trial NCT00772304?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2008-10.
What conditions does trial NCT00772304 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00772304?
The interventions under investigation include: Olopatadine 0.6% / Azelastine 137 mcg (DRUG).
Who is sponsoring clinical trial NCT00772304?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00772304 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00772304's enrollment target sits among peer trials
102 6th of 23 higher than 18 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
COMPLETED · Phase 4
-
Comparability and Standardization of Controlled Allergen Challenge Facilities
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia